[Federal Register Volume 77, Number 144 (Thursday, July 26, 2012)]
[Notices]
[Page 43861]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-18206]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice Of Application; Cody 
Laboratories, Inc.

    Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this 
is notice that on May 30, 2012, Cody Laboratories Inc., 601 Yellowstone 
Avenue, Cody, Wyoming 82414-9321, made application by renewal to the 
Drug Enforcement Administration (DEA) for registration as an importer 
of the following basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Opium, Raw (9600)..........................  II
Concentrate Poppy Straw (9670).............  II
Tapentadol (9780)..........................  II
------------------------------------------------------------------------

    The company plans to import narcotic raw materials for 
manufacturing and further distribution to its customers. The company is 
registered with DEA as a manufacturer of several controlled substances 
that are manufactured from opium, poppy straw, and poppy straw 
concentrate.
    The company plans to import an intermediate form of Tapentadol 
(9780) to bulk manufacture Tapentadol for distribution to its 
customers.
    Comments and requests for hearings on applications to import 
narcotic raw material are not appropriate. 72 FR 3417 (2007).
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic class of controlled 
substance listed in schedule II, which fall under the authority of 
section 1002(a)(2)(B) of the Act [21 U.S.C. 952(a)(2)(B)] may, in the 
circumstances set forth in 21 U.S.C. 958(i), file comments or 
objections to the issuance of the proposed registration and may, at the 
same time, file a written request for a hearing on such application 
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 
1316.47.
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than August 27, 2012.
    As noted in a previous notice published in the Federal Register on 
September 23, 1975, 40 FR 43745, all applicants for registration to 
import a basic class of any controlled substance in schedule I or II 
are, and will continue to be, required to demonstrate to the Deputy 
Assistant Administrator, Office of Diversion Control, Drug Enforcement 
Administration, that the requirements for such registration pursuant to 
21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), 
(e), and (f) are satisfied.

    Dated: July 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-18206 Filed 7-25-12; 8:45 am]
BILLING CODE 4410-09-P